Anirban Maitra, Laura and Isaac Perlmutter Professor of Pathology and Director of the Perlmutter Cancer Center, shared on LinkedIn:
“The NYU Langone Health KRAS Excellence Initiative is the one stop website to find KRAS targeted clinical trials that are either enrolling or soon to be activated at the Perlmutter Cancer Center.
You can find all the relevant information at: KRAS Excellence Initiative
The latest trial to be activated is Verastem Oncology KRAS G12D inhibitor (VS-7375) in KRAS G12D mutated solid cancers (site PI Kristen Spencer).”
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Other articles about Solid tumors on OncoDaily.